Figure 1: Relationship of SLCO1B1 (c.388A>G; c.521T>C ) and SLCO2B1 (c.-71T>C) genotypes (A) and haplotypes (B) on tacrolimus dose-adjusted concentration (CO/D) through three-month treatment. *P< 0.05 as compared by Two-Way Repeated Measures Analysis of Variance followed by Hom-Sidak method. Note: Different number of subjects (n=123 for c.388A>G and SLCO1B1 haplotype; n =128 for c.521T>C) are observed among the figures because some information on dose or tacrolimus in a time set was missing.